BlossomHill Therapeutics Closes $100M Series B
By Yeji Jesse Lee · February 29, 2024, 8:16 PM EST
Biotechnology company BlossomHill Therapeutics has raised a $100 million Series B financing round to advance its pipeline of cancer and autoimmune treatments, the company announced Thursday....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login